Biotech Values

[maverick_1]

ONCE: The necessary SPARK for biotech revival

Excerpted from today's NYT::http://www.nytimes.com/2015/10/05/science/eye-treatment-closes-in-on-being-first-gene-therapy-approved-in-us.html?ref=business&_r=0

“We saw substantial restoration of vision in patients who were progressing toward complete blindness,” Dr. Albert M. Maguire, a professor of ophthalmology at the University of Pennsylvania and a lead researcher in the study, said in a news release being issued by Spark.

Dr. Katherine High, Spark’s president and chief scientific officer, said this was the first successful randomized, controlled trial for any gene therapy aimed at an inherited disease.

“I’ve been working in gene therapy for most of my career,” she said. “It’s been a long time coming, and I’m delighted.”

Besides encouraging the once beleaguered field of gene therapy, the results — if interpreted positively by investors — could help lift biotechnology stocks, which have been battered recently by concerns over a backlash against high drug prices.

AND finally the renown Children's Hospital of Philly reaps a huge reward for it's VISION!